APOE4依赖的胆碱能/多巴胺能系统对阿尔茨海默病谱系临床症状的贡献
本研究回顾性分析387例淀粉样蛋白确认的AD谱系患者,按APOE4状态分为205例携带者和182例非携带者。结果显示携带者基底前脑体积降低更突出且与记忆障碍和AD典型灌注减低相关,非携带者纹状体多巴胺转运体摄取降低更突出且与广泛认知域和神经精神症状相关。
要点
- APOE4携带者基底前脑体积降低更明显,与记忆障碍和颞顶叶灌注减低相关。
- APOE4非携带者纹状体DAT摄取降低更明显,与广泛认知域和幻觉、妄想、焦虑相关。
- 胆碱能或多巴胺能影像标志物与症状的关联模式随APOE4状态不同。
核心结论
- APOE4状态与AD中胆碱能和多巴胺能退变的临床及脑灌注相关模式差异有关。
研究设计与样本
- 回顾性观察研究纳入387例淀粉样蛋白确认的AD谱系患者,按APOE4状态分为205例携带者和182例非携带者。
- 评估基底前脑体积、纹状体多巴胺转运体摄取和区域脑灌注与认知表现及神经精神 Inventory 评分的关系。
主要发现
- APOE4携带者基底前脑体积低于非携带者,而非携带者纹状体DAT摄取更低。
- 携带者中较低基底前脑体积与记忆障碍和AD典型颞顶叶灌注减低相关,纳入后扣带回灌注后基底前脑体积-记忆关联减弱。
- 携带者中较低基底前脑体积还与幻觉、妄想、焦虑、淡漠、异常运动行为和食欲改变相关,校正区域灌注后幻觉、妄想和淡漠的直接关联仍存在。
- 非携带者中较低DAT与广泛认知域表现较差及幻觉、妄想和焦虑相关,校正区域灌注后这些DAT关联大多持续存在。
临床怎么用
- 在AD谱系患者中解读胆碱能或多巴胺能影像标志物时,可结合APOE4状态理解其与认知和神经精神症状的关联差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical heterogeneity in Alzheimer's disease (AD) may reflect differential involvement of neurotransmitter systems, but whether the associations of cholinergic and dopaminergic imaging biomarkers with cognitive and neuropsychiatric symptoms differ according to apolipoprotein E ε4 (APOE4) status remains unclear. METHODS: We studied 387 patients across the amyloid-confirmed AD spectrum. Patients were stratified by APOE4 status into 205 carriers and 182 non-carriers. Basal forebrain volume (BFV), striatal dopamine transporter uptake (DAT), and regional brain perfusion were examined in relation to cognitive performance and neuropsychiatric inventory scores. RESULTS: APOE4 carriers showed lower BFV than non-carriers, whereas APOE4 non-carriers showed lower DAT. In APOE4 carriers, lower BFV was associated with memory dysfunction and AD-typical temporoparietal hypoperfusion; the BFV-memory association was attenuated after inclusion of posterior cingulate perfusion. Lower BFV was also associated with several neuropsychiatric symptoms, including hallucinations, delusions, anxiety, apathy, aberrant motor behavior, and appetite changes, with direct associations remaining for hallucinations, delusions, and apathy after accounting for regional perfusion. In APOE4 non-carriers, lower DAT was associated with poorer performance across widespread cognitive domains and with hallucinations, delusions, and anxiety. These DAT associations largely persisted even after adjustment for regional perfusion. CONCLUSION: APOE4 status was associated with differences in the clinical and brain perfusion correlates of cholinergic and dopaminergic degeneration in AD. APOE4 carriers showed a BFV-dominant pattern linked to AD-typical perfusion changes and memory dysfunction, whereas non-carriers showed a DAT-dominant pattern with largely perfusion-independent associations with cognitive and neuropsychiatric manifestations.
引用
- Kang S, Jeon S, Lee D, et al. APOE4-dependent cholinergic/dopaminergic contributions to clinical symptoms across Alzheimer's disease spectrum: A retrospective observational study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42714593. doi:10.1007/s00259-026-08165-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。